Abstract-The angiotensin receptor blocker losartan mitigated cerebrovascular and cognitive deficits in mouse models of Alzheimer disease, in line with some clinical evidence of reduced onset and progression to Alzheimer disease. We investigated whether these benefits apply to another angiotensin receptor blocker, namely candesartan. Adult transgenic mice overexpressing a mutated form of the human APP (amyloid precursor protein) and wild-type controls were treated with vehicle or candesartan (cohort 1: 2 months, 1 mg/kg per day, osmotic subcutaneous minipumps; cohort 2: 5 months, 10 mg/kg per day in drinking water). Candesartan largely restored endothelial and smooth muscle function and reduced neuroinflammation in both cohorts, without improving sensory evoked cerebral blood flow responses. Candesartan exerted restorative effects on the reduced number of Ki67-immunopositive proliferating cells in the granule cell layer of the hippocampus but not on that of DCX (doublecortin)-positive immature granule cells, despite normalizing the length of their dendritic projections in the molecular layer. Amyloid plaque load and impaired cognitive function were unaltered by candesartan, and blood pressure was decreased in treated APP and wild-type mice. Overall, findings show that candesartan shared several advantages reported previously for losartan, but it exhibited limited cognitive benefits and stronger blood pressure lowering effects. The choice of angiotensin receptor blocker may thus be critical for therapeutic efficacy in patients with vascular diseases at high risk of developing Alzheimer disease.
A lzheimer disease (AD) is often studied from a neuronal perspective whereby amyloid plaques and tangles are considered to be central to disease pathogenesis. However, accumulating evidence supports a strong vascular contribution to sporadic AD, which can affect age of onset. 1 Hypertension is a primary vascular risk factor for sporadic AD such that elderly patients with untreated mild hypertension have higher conversion rates to AD relative to healthy elderly controls. 2 Hypertension and its relation to AD has led to the renin-angiotensin system (RAS) becoming a pathway of interest. The brain RAS contains all necessary peptides, enzymes, and receptors for an active central function. Ang II (Angiotensin II) binding to either the AT1R (Ang II type 1 receptor) or AT2R (type 2 receptor) and binding of the active peptide Ang IV (angiotensin IV) to AT4R (Ang IV receptor) have been associated with vascular, neuronal, and cognitive effects. [3] [4] [5] [6] Evidence from large cohort studies report lower incidence of dementia in individuals consuming angiotensin receptor blockers (ARBs) to treat their hypertension. 7 Treatment of patients with mild cognitive impairment with ARBs resulted in 33% less conversion to AD and showed slower cognitive decline compared with those not receiving ARBs. 8 In contrast, a large meta-analysis revealed no benefit of ARBs in delaying AD onset. 9 Thus, evaluating the potential benefits of antihypertensive medications and how they modify the risk of developing AD is important.
Abnormalities in the central RAS have been reported in AD, 7 and RAS modulation with ARBs has shown promise in animal models, which led to current clinical trials for telmisartan (URL: http://www.clinicaltrials.gov. Unique identifier: NCT02085265), losartan (URL: http://www.clinicaltrials.gov. Unique identifier: NCT02913664), and candesartan (URL: http://www.clinicaltrials.gov. Unique identifier: NCT02646982). In various AD mouse models, positive effects on AD-related pathology have been found after intranasal administration of candesartan, 10 telmisartan, 11 or losartan, 12 and orally with olmesartan. 13 Particularly, our group 14 found that losartan administered to a transgenic mouse model of AD overexpressing a mutated form of the human APP (amyloid precursor protein) mice rescued cerebrovascular function and spatial memory. Additional benefits included neurogenic, antioxidant and anti-inflammatory properties, and normalization of RAS peptide receptors levels. Given the differences in individual ARB properties, ability to cross the blood-brain barrier, candesartan having the greatest permeability, 15 and the growing interest for candesartan as a potential therapy for AD, 16 we sought to investigate whether it would have therapeutic benefits in APP mice.
Candesartan was selected for being the strongest AT1R antagonist compared with other ARBs, 17 its documented ability to cross the blood-brain barrier in control rats, 18 and for its protective effects on cognition in models of traumatic brain injury 19 and ischemia. 20 Two separate cohorts were treated with candesartan (2 or 5 months either subcutaneously or orally). We found no cognitive rescue in either cohort, despite neurogenic benefits, reduced cortical inflammation, and improved vascular reactivity to endothelial-and smooth muscle celldependent vasodilators. Our results point to drug-specific therapeutic effects for losartan as seen in previous studies 14, 21 that are not shared by candesartan, suggesting that some ARBs may be more therapeutically beneficial than others in AD.
Methods
The raw data that support the findings presented in this article are available from the corresponding author upon reasonable request.
Animals and Treatments
Experiments were approved by the Animal Ethics Committee of the Montreal Neurological Institute and complied with the Canadian Council on Animal Care. All in vivo and vascular reactivity experiments were performed blind by the experimenter and analyzed by another colleague that replaced cage cards identifying the mice with new blind cage and mouse ID numbers. Heterozygous male and female C57BL6 mice (3-4 months old) carrying the familial Swedish (K670N, M671L) and Indiana (V717F) human APP mutations directed by the PDGF (platelet-derived growth factor)-chain promoter (APP mice, J20 line) 22 and their wild-type (WT) littermates were used in approximately equal number (in cohort 1, 61% of mice were male and in cohort 2 there were an equal number of each sex). In cohort 1, WT and APP mice were randomized to receive either vehicle (25% dimethyl sulfoxide, n=11 WT and 7 APP mice) or candesartan (C0253, LKT laboratories, 1 mg/kg per day, n=10 mice/group) through subcutaneous osmotic minipumps (ALZET, Cupertino, CA: model 1004; delivering 0.11 mL/h for 28 days), as previously described.
14 Mice were tested in the Morris water maze (MWM1) during the last week of treatment (see below). Because no behavioral improvements were detected, new pumps were implanted after 34 days for a total treatment period of 2 months, after which MWM2 was performed (end point: 5-6 months). Mice in cohort 2 were randomized to be treated orally or not with candesartan (≈10 mg/kg per day, 5 months) through the drinking water with MWM testing after 3, 4, and 5 months of treatment (end point: 8-9 months). WT (n=12) and APP (n=11) control groups received vehicle (10% polyethylene glycol 400, 5% ethanol, and 2% cremophor) adjusted to pH 9 with 0.2 mol/L Na 2 CO 3 , while the treated groups (n=11 WT and 12 APP mice) received candesartan celexetil ester (C0254, LKT Laboratories, dissolved in vehicle).
Blood Pressure Measurement
Blood pressure (BP) was measured before behavioral testing using noninvasive tail-cuff plethysmography (Kent Scientific Company). Mice were habituated to the restraining device and tail cuffs for 10 min/d for 3 days before measurements. Ten additional acclimation cycles were performed before acquiring 5 measurements of systolic, diastolic, and mean BP.
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Behavior
Spatial memory was evaluated in the MWM, as described previously. 23 For MWM1, there was a minimum of 3 visible platform training days, fewer visible days were performed on subsequent mazes because of task familiarity. To assess spatial learning, spatial visual cues were changed, and the platform was submerged underwater in a new location. Twenty-four hours after the last session, a probe trial was conducted to assess spatial memory. Data were recorded using the 2020 Plus tracking system and Water 2020 software (Ganz FC62D video camera; HVS Image, Buckingham, United Kingdom).
Laser Doppler Flowmetry
Laser Doppler flowmetry was used to measure changes in cerebral blood flow in response to stimulation (20 seconds, 8-10 Hz) of the right whiskers using an electric toothbrush. 23 Mice (n=4-6 mice/ group) were anesthetized (ketamine 85 mg/kg and xylazine 3 mg/kg IM) and placed in a stereotaxic frame to thin the bone over the left somatosensory cortex. Cerebral blood flow was continuously recorded using a laser Doppler probe (Transonic Systems Inc, Ithaca, NY) before, during, and after whisker stimulation. Four to 6 recordings were acquired for each mouse, and maximal responses averaged and expressed as the peak percent change relative to baseline. All mice's baseline blood flow was between 10 and 20 arbitrary units.
Vascular Reactivity
Diameter of isolated and pressurized (60 mm Hg) segments of the middle or posterior cerebral arteries (n=3-5/group) was measured using video microscopy (Living Systems Instrumental, Burlington, VT). 23 
Western Blots
Dissected cortices and hippocampi (n=4 mice/group) were solubilized in lysis buffer (18.5 mL dH 2 O, 400 μL 1 mol/L Tris-HCl, 600 μL 5 mol/L NaCl, 200 μL 10% NP40, 200 μL glycerol, 100 μL 200 mmol/L NaV (sodium orthovanadate), and 2 protease inhibitor cocktail tablets), homogenized, and centrifuged. Proteins were assayed, separated by sodium dodecyl sulfate gel, and transferred to a nitrocellulose membrane. Membranes were incubated (4×15 minutes) in 7% blocking solution and then overnight with either a mouse anti-AT1R (1:200), 24 anti-AT2R (1:200), 24 or anti-β-actin (1:10000, Sigma Aldrich), rabbit anti-AT4R (1:500, Cell Signaling Technology), or anti-BDNF (brain-derived neurotrophic factor, 1:1500, Alomone). Membranes were incubated (1 hour) with horseradish peroxidaseconjugated anti-mouse (1:1000) or anti-rabbit (1:2000) secondary antibodies (Jackson ImmunoResearch), developed using Western Sure Premium Chemiluminescent substrate (LI-COR kit; Lincoln, NE), and scanned using a C-Digit Blot scanner (STORM 860, GE Health Care, Piscataway, NJ). Densitometry was quantified with Image Studio Digit software version 5.
Immunohistochemistry
Mice (n=4-5/group) were perfused intracardially with 4% paraformaldehyde; brains were postfixed overnight (4% paraformaldehyde), cryoprotected (30% sucrose, 48 hours), frozen in isopentane and stored at −80°C. Coronal sections (25 μm) were obtained on a freezing microtome, and immunostained (2-3 sections/mouse) for diffuse (anti-6E10, 1:800; Covance, CA) and mature dense core (1% Thioflavin-S, 8 , and immunodetection with 3'3-diaminobenzidine or slate gray staining kits (Vector Laboratories). Low-power digital images were acquired using a Leitz Aristoplan microscope equipped with epifluorescence, and areas of interest were manually delineated for analysis.
Statistical Analysis
Percentage area occupied by Thioflavin-S, 6E10, GFAP, Iba-1, or SOD2 was quantified using MetaMorph (version 6.1r3 software, Universal Imaging, Downingtown, PA). Number of Ki67 and DCXimmunopositive cells in the granule cell layer of the dentate gyrus were counted directly under the microscope. To measure dendritic arborization of DCX cells, the length of the longest dendrites was measured on digital pictures and expressed as a percent of the molecular cell layer thickness. Aβ plaque load between APP groups was compared using unpaired t tests; all other comparisons required 2-way ANOVAs (factors: genotype and treatment) followed by a Newman-Keuls post hoc multiple comparison test. Effect sizes (η 2 ) were calculated using the sum of squares. Analyses were performed using GraphPad Prism 7, P≤0.05 was significant. In figures, blue graphs are results from cohort 1 and green from cohort 2.
Results
Candesartan Exerted Limited Cognitive Improvements
In cohort 1, MWM1 performed after 1 month of treatment showed no differences between APP groups (data not shown). After a second month of treatment, spatial learning in APP groups was still impaired compared with WT controls ( Figure 1A) . Similarly, spatial memory remained impaired in APP groups compared with WT ( Figure 1B) . After 3 months of treatment in cohort 2, there were no differences between APP groups in spatial learning or memory ( Figure S1A and S1B in the online-only Data Supplement). After 4 months, there was 1 day during the learning portion of the task where treated APP mice performed significantly better than APP controls, and there was a tendency towards improved memory performance in the probe trial ( Figure S1C and S1D). After the fifth month of treatment, APP mouse performance was in between that of WT and APP controls for spatial learning; significantly improved compared with APP controls on day 5, however, still different from WT groups ( Figure 1C ). In the probe trial, the tendency is seen at 4 months for treated APP mice to have improved spatial memory ( Figure S1 ) was still present after 5 months, albeit not significant after multiple comparisons ( Figure 1D ). In both cohorts, candesartan significantly reduced BP by 25% in both WT and APP groups in cohort 1 (Figure 2A ) compared with their respective untreated control groups and by 38% for WT and 25% for APP mice in cohort 2 ( Figure 2B ). Despite this decrease in BP, the increase in whisker-evoked cerebral blood flow measured in vivo in treated WT mice was not altered, and no treatment benefit was found in APP mice ( Figure 2C through 2F) .
Candesartan Improved Cerebrovascular Reactivity
Candesartan improved responses to both endothelial-dependent dilator acetylcholine and smooth muscle relaxant calcitonin gene-related peptide in isolated vessels. Recovery for acetylcholine was complete in cohort 1, and mostly in cohort 2 where APP-C mice differed from WT groups only at the highest concentration ( Figure 3A and 3B). NO bioavailability in the vessel wall was significantly reduced in untreated APP mice from both cohorts compared with WT groups, and candesartan fully normalized this response in APP mice from cohort 1, but not significantly in cohort 2 ( Figures 3E and  3F ). Differences in receptor affinity between groups were not detected (Table S1 ). As TRPV4 channels are involved in acetylcholine-mediated dilation, 25 responses to GSK, a TRPV4 channel opener were tested. GSK responses were recovered by candesartan in APP mice from cohort 1 and from cohort 2 where treated APP mice differed from WT groups only at a single concentration (10 -6 mol/L; Figure 3A and 3B). Similar to calcitonin gene-related peptide, dilations induced by K ATP channels that mediate part of the calcitonin gene-related peptide response were fully rescued by candesartan in APP mice from both cohorts, as measured with levcromakalim ( Figure 3C and 3D) .
Candesartan Did Not Affect Central RAS Receptor Expression
In cohort 1, there were no significant differences in AT1R, AT2R, and AT4R ( Figure 4A , 4C, and 4E) protein levels in cortex and hippocampus between all groups. In cohort 2, there was a main effect of genotype on cortical and hippocampal AT1R levels whereby APP mice had higher levels compared with WT controls, but post hoc analyses showed significance only in the hippocampus ( Figure 4B) . No differences in cortical AT2R levels were noted in either cohort. There was a significant main effect of treatment on hippocampal AT2R in cohort 2, but post hoc analyses revealed significance only between WT and treated APP mice ( Figure 4D ). Although no differences were found between groups in cortical or hippocampal AT4R levels ( Figure 4F ), there was a main effect of candesartan to decrease hippocampal AT4R in both WT and APP groups in cohort 2, F(1, 12)=5.23; P<0.05 (η 2 =0.30).
Candesartan Did Not Alter Aβ Pathology and Oxidative Stress but Reduced Neuroinflammation
Aβ plaques were undetectable in APP brains from cohort 1 because of their young age and were not quantified. In cohort 2, Aβ plaque load in cortex and hippocampus quantified with Thioflavin-S staining and 6E10 immunolabeling was not affected by candesartan ( Figure 5A through 5D ). Western blot analyses of APP and 56 kDa protein levels in cortex showed no effect of candesartan ( Figure 5E ). An additional 9 kDa band was detected in the hippocampus, but levels remained unchanged by candesartan, as was the case for APP levels. However, hippocampal protein levels of the 56 kDa band were significantly reduced (29.5%, P<0.05) in candesartan treated compared with untreated APP mice ( Figure 5F ). Mitochondrial oxidative stress assessed by SOD2 immunolabeling ( Figure S2 ) or protein levels (Western blots, data not shown) was not increased in APP mice compared with WT controls, and candesartan exerted no effect in either cohort. GFAP-immunopositive reactive astrocytes ( Figure 6A ) and Iba-1-immunopositive activated microglia ( Figure 6B ) were significantly increased in cortex of APP mice in both cohorts and significantly reduced by treatment.
Candesartan Increased Cellular Proliferation and Dendritic Arborization
A reduced number of Ki67-immunopositive cells was found in the dentate gyrus of APP compared with WT mice in both cohorts ( Figure 6C ). Candesartan significantly increased , and AT4R (Angiotensin II type 4 receptor) protein levels were found in the cortex of APP (amyloid precursor protein) mice in cohort 1, and C did not alter these levels (A, C, and E). In cohort 2, APP mice had slightly, albeit not significant, higher AT1R levels in hippocampus compared with wild type (WT), and this tendency became significant after C treatment (B). C treatment in APP mice from cohort 2 resulted in a significant increase in hippocampal AT2R levels compared with WT controls (D) and no significant differences in AT4R levels (F). *P<0.05, **P<0.01.
this number in both cohorts. When looking at DCXimmunopositive cells ( Figure 6D ), APP mice displayed significantly reduced number and shorter dendrites compared with WT mice in both cohorts ( Figure 6D ). Although candesartan did not increase the number of DCX cells in either cohort, the dendrites of the remaining cells in treated APP mice extended much longer than APP controls within the molecular layer, reaching a level of extension similar to WT mice. Although there was a tendency for a main effect of treatment in cohort 1 for hippocampal BDNF, it was not significant ( Figure 6E ). In cohort 2, APP groups had higher levels of BDNF compared with WT groups, and there was a main effect of treatment F(1, 12)=31.46, P<0.001 (η 2 =0.27), whereby candesartan significantly increased BDNF levels in both WT and APP mice ( Figure 6E ).
Discussion
ARBs exert neuroprotective, vasodilatory, and anti-inflammatory properties, all of which are of interest in preventing and possibly treating AD. However, epidemiological studies have shown conflicting results when investigating the protective effects of ARBs in dementia, some reporting delayed onset for individuals prescribed ARBs to treat hypertension, 7 whereas others report no significant difference in age of onset despite ARB use. 9 This discrepancy could be attributed to different pharmacological profiles among ARBs. For instance, losartan is the only surmountable AT1R antagonist while candesartan is a long lasting, highly potent insurmountable AT1R antagonist. 17 Telmisartan, irbesartan, and candesartan have PPAR-γ (peroxisome proliferator-activated receptor-γ) agonist properties; PPAR-γ is a nuclear hormone receptor involved in the regulation of inflammation, oxidative stress, and apoptosis. 26 We found that candesartan exerted potent anti-inflammatory effects, increased markers of neurogenesis, and mostly restored cerebrovascular reactivity to vasodilators, but had no, or limited benefits on cognition. One effect of candesartan not observed with losartan 14 and not reported for intranasal telmisartan 11 or candesartan, 10 was its BP-lowering effects, 17 which should be considered with caution as hypotension has been linked to poor cognitive performance. 27 Our findings point to a drug-specific effect of losartan and suggest that PPAR-γ agonist properties are not needed for cognitive recovery, but they do not exclude the possibility that dose or treatment duration of candesartan may need to be adjusted to beneficially impact cognition.
Cognitive Deficits in APP Mice and Candesartan
Cognitive deficits in AD mouse models have been prevented or rescued by losartan 14, 21 and other ARBs, 11, 28 and candesartan has shown benefits on memory after traumatic brain injury 19 and ischemia 20 in mice following a similar treatment regimen as ours. We found no or limited improvement on spatial learning after 2 and 5 months of candesartan treatment. This supports previous studies that failed to see cognitive recovery in AD mouse models with valsartan 29 and olmesartan, 13 which both lowered BP.
Candesartan did not alter AT1R levels; however, a main effect of candesartan resulted in a concurrent raise in AT2R levels and reduction in AT4R levels in both WT and APP mice. Because both receptor subtypes are implicated in vasodilation and memory, 30 the downregulation of AT4R by candesartan may have contributed to its lack of benefits on spatial learning and memory, suggesting a more important role for AT4Rs than AT2Rs in the context of memory.
Candesartan's PPAR-γ agonist properties have been proposed as an added benefit. 28 However, our findings do not support such an advantage in rescuing memory function in AD Figure 6 . Candesartan (C) exerts anti-inflammatory and neurogenic effects. Activation of cortical astrocytes and microglia as quantified with GFAP (glial fibrillary acidic protein; A) and Iba-1 (B) immunostaining was significantly reduced by C. C treatment did not increase the number of Ki67-positive cells in the granule cell layer (GCL) of the dentate gyrus in APP (amyloid precursor protein) mice from cohort 1 but did in cohort 2 (C). C treatment exerted no benefits on number of immature neurons in the GCL labeled with DCX (doublecortin; D). However, the dendritic length from DCX cells projecting in the molecular layer (ML) was increased by C treatment in APP mice (D). Hippocampal BDNF (brain-derived neurotrophic factor) did not differ between groups in cohort 1, but they were higher in APP mice from cohort 2 compared with wild-type (WT) controls (E), an increase potentiated by C treatment. Scale bars=200 μm for GFAP and Iba-1 (insets 50 μm), 100 μm for Ki67 and DCX. SLM indicates stratum lacunosum molecular. *P<0.05, **P<0.01, ***P<0.001. mice, as also seen in an lipopolysaccharide-induced inflammatory model concomitantly treated with telmisartan and PPAR-γ antagonist that reported cognitive improvement independent of PPAR-γ activity. 31 Likewise, adult J20 APP mice treated with the PPAR-γ agonist pioglitazone showed no cognitive benefits. 32 Additionally, a large Scandinavian study investigating candesartan administration during the acute phase of stroke found harmful effects on cognition 6 months after the intervention.
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Candesartan and Hippocampal Cellular Proliferation, Dendritic Arborization, and Aβ Pathology APP mice display neuronal loss, 22 lessening the opportunity for synaptogenesis. Here, we found that candesartan increased the number of newborn Ki67-positive cells in the dentate gyrus. This neurogenic effect may be attributed to increased AT2R levels, whose activation has been associated with enhanced neurite outgrowth and neurogenesis. 34, 35 Candesartan also significantly improved the dendrite extension of immature DCX cells in the molecular layer where they receive afferents from the perforant path, the first line of entry in the hippocampal memory pathway. Yet, despite these neurogenic benefits, cognitive improvement was not observed.
Candesartan exerted limited effects on the Aβ pathology, noting only a slight decrease in the hippocampal 56 kDa Aβ oligomers, a species previously associated with memory deficits in APP mice. 36 However, failure of candesartan to improve memory suggests the 56 kDa species is not a promising target in AD, in agreement with cognitively effective therapies that failed to reduce the Aβ pathology in APP mice. 14, 23, 28 Other studies with valsartan reduced Aβ burden but had no cognitive benefits, 29 and Torika et al 10 found reduced hippocampal Aβ plaque load after intranasal candesartan, but memory was not tested. As ARBs have been shown to block the AT1R-mediated effect of Ang II favoring the nonamyloidogenic pathway of APP cleavage, 37 the unaltered amyloidosis seen with candesartan treatment here is in line with such findings. Because losartan failed to counter Aβ pathology yet rescued spatial learning and memory in APP mice, 14 we conclude that candesartan's lack of cognitive benefits cannot be imputed to its failure to decrease Aβ pathology.
Candesartan Effects on Neuroinflammation
Astrocytes and microglial cells become activated in response to Aβ pathology, resulting in chronic release of proinflammatory cytokines in AD. 38 Our findings of anti-inflammatory properties of candesartan are supported by several studies reporting its ability to reduce brain inflammation in the 5×FAD mouse model, 10 microglia activation and macrophage infiltration in lipopolysaccharide-induced inflammation, 39 hypertension, 40 traumatic brain injury, 19 and cerebral ischemia. 20 Yet, despite candesartan's ability to reduce neuroinflammation, this was not associated with cognitive benefits similar to the PPAR-γ agonist pioglitazone 32 and the angiotensin-converting enzyme inhibitor enalapril. 41 
Cerebrovascular Reactivity and Neurovascular Coupling
APP mice display the expected impairments in dilatory responses, 42 which were restored by candesartan. However, candesartan failed to rescue NO bioavailability in cohort 2. It is thus possible that delivery of candesartan through osmotic minipumps (cohort 1) compared with drinking water (cohort 2) allowed for better control of drug concentration and steady-state levels that conferred a better drug efficacy despite a shorter treatment, at least on NO synthesis. Alternatively, different mechanisms may underlie NO reduction in APP mice through aging, making it more difficult to recover. Interestingly, vasorelaxant effects of AT4R activation have been linked to NO synthase activation. 3 It is thus possible that candesartan failed to rescue NO bioavailability in APP mice in cohort 2 because of a combined preexisting low NO levels in the vessel wall, and reducing effect of candesartan on AT4Rs, as seen in the hippocampus.
The tight communication between neurons, astrocytes, and brain vasculature termed neurovascular coupling is impaired in APP mice. 23 This impaired response was not improved by candesartan in either cohort, despite its benefits on cerebrovascular dilatory responses and astrocyte activation. It could also be argued that failure of candesartan to rescue NO bioavailability, particularly in cohort 2, could explain lack of functional recovery. However, a clear explanation for unrecovered sensory evoked neurovascular coupling in cohort 1 cannot be provided with the current results. Further investigations could reveal alterations in the neuronal response to whisker stimulation or that intraparenchymal capillaries, a vascular segment recently implicated in arteriole dilation, 43, 44 are affected differently than pial vessels by the disease process and candesartan treatment.
Perspectives
Our study shows several benefits of candesartan, but also points to its limits in rescuing memory in APP mice, the most important clinical feature of the disease, suggesting that all ARBs may not have the same cognitive properties. However, alternative explanations could be that a lower dose may be more beneficial for cognition, that a longer treatment period may be required, disease stage is important, or that the PPAR-γ agonist property of candesartan does not confer an added value in treating dementia. We conclude that candesartan does not seem to be a promising therapeutic avenue for patients with vascular diseases at high risk of developing AD and this should be taken into consideration in the treatment of hypertension.
